证券代码：000953 证券简称：*ST 河化 广西河池化工股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | --- | |------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------|-------------|----------------------| | | | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | ■其他（参加 2021 | 年广西辖区上市公司投资者网上集体接待 | | | | | 日暨 2020 | 年度业绩说明会活动） | | | | 参与单位名称及 | 参加 2021 | 年广 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥37,976,698.50, a decrease of 5.29% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥5,731,820.08, representing a significant decline of 1,452.50% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥5,795,516.42, a decrease of 11,086.85% compared to the previous year[5]. - Total operating revenue for the period was CNY 131,888,715.06, a decrease of 1.1% compared to CNY 133,381,231.81 in the previous period[18]. - Net profit for the third quarter was a loss of ¥4,041,708.17, compared to a profit of ¥3,866,625.39 in the same period last year, indicating a significant decline[20]. - Operating profit turned negative at ¥-4,024,899.09, down from ¥4,721,083.41 in the previous year[19]. - The company reported a total comprehensive income of ¥-4,041,708.17, compared to ¥3,866,625.39 in the previous year[20]. - Basic and diluted earnings per share were both ¥-0.0112, compared to ¥0.0090 in the same quarter last year[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥372,353,452.42, down 6.07% from the end of the previous year[5]. - Total assets decreased to CNY 372,353,452.42 from CNY 396,411,315.40, reflecting a decline of 6.1%[16]. - Total liabilities decreased to CNY 181,618,317.70 from CNY 202,272,965.76, a reduction of 10.2%[16]. - The company’s non-current assets increased slightly to CNY 246,701,910.38 from CNY 241,285,798.75, an increase of 2.4%[15]. - The company’s retained earnings showed a slight decline, with a balance of CNY -710,612,948.36 compared to CNY -706,515,946.95 in the previous period[16]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥3,538,796.92, a decrease of 55.69% compared to the same period last year[5]. - Cash flow from operating activities generated ¥3,538,796.92, a decrease of 55.7% compared to ¥7,985,606.47 in the prior year[21]. - Cash flow from investment activities yielded a net inflow of ¥24,919,237.25, up from ¥6,443,147.62 year-over-year[22]. - The company’s cash and cash equivalents at the end of the period totaled ¥64,153,407.11, down from ¥68,159,883.04 at the end of the previous year[22]. - Cash and cash equivalents increased to CNY 64,153,407.11 from CNY 35,685,903.67, representing an increase of 79.5%[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,695[10]. - The largest shareholder, Ningbo Yinyi Holdings Co., Ltd., held 23.76% of the shares, with 87,000,000 shares pledged[10]. Research and Development - The company's R&D expenses decreased by 46.19% year-on-year to ¥3,087,644.84, due to optimization of the R&D personnel structure[9]. - Research and development expenses decreased to ¥3,087,644.84 from ¥5,738,149.25, reflecting a reduction of approximately 46%[19]. Inventory and Operating Costs - The company's inventory increased by 45.05% to ¥34,548,875.93, primarily due to an increase in stock of finished goods[9]. - Inventory rose to CNY 34,548,875.93, up from CNY 23,818,434.02, indicating a growth of 45.2%[15]. - Total operating costs increased to ¥142,417,525.67 from ¥131,518,124.41, representing an increase of approximately 8.4% year-over-year[19]. Legal and Investment Activities - The company won a lawsuit against Alkaloida Chemical Company, receiving a total of USD 673,500 in goods and USD 271,401.39 in penalties[12]. - The company plans to invest CNY 44,519,300 in the technical transformation of production lines and multi-functional pilot workshops[13]. Credit Impairment - The company incurred a credit impairment loss of ¥5,165,633.90, significantly higher than ¥669,137.58 in the same period last year[19].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 93,912,016.56, representing a 0.67% increase compared to CNY 93,283,962.41 in the same period last year[24]. - The net profit attributable to shareholders decreased by 42.77% to CNY 1,634,818.67 from CNY 2,856,763.21 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was CNY -3,340,425.88, a decline of 290.69% compared to CNY 1,751,745.52 in the previous year[24]. - Basic earnings per share decreased by 42.31% to CNY 0.0045 from CNY 0.0078 in the previous year[24]. - The weighted average return on equity was 0.92%, down 0.78% from 1.70% in the same period last year[24]. - The company reported a total investment income of CNY 569,366.44, contributing 18.77% to the total profit, primarily from the sale of bank wealth management products[47]. - The total comprehensive income for the first half of 2022 was CNY 1,999,808.03, down from CNY 3,349,624.24 in the same period of 2021, indicating a decrease of about 40.4%[138]. Cash Flow and Assets - The net cash flow from operating activities increased by 68.06% to CNY 12,395,475.38 from CNY 7,375,714.21 in the same period last year[24]. - The net cash flow from investment activities for the first half of 2022 was CNY 17,542,602.30, a decrease from CNY 19,423,406.20 in the same period of 2021, reflecting a decline of approximately 4.5%[140]. - The total cash and cash equivalents at the end of the first half of 2022 amounted to CNY 65,706,750.20, down from CNY 80,607,138.98 at the end of the first half of 2021, representing a decrease of about 18.5%[140]. - The company's total assets at the end of the reporting period were CNY 387,067,545.92, down 2.36% from CNY 396,411,315.40 at the end of the previous year[24]. - The net increase in cash and cash equivalents was CNY 30,020,846.53, representing a 17.79% increase from CNY 25,486,585.24 in the previous year[46]. Operational Highlights - The company is primarily engaged in the research, production, and sales of pharmaceutical intermediates and urea processing and sales[32]. - The operating cost increased by 21.99% to 87,946,455.24 yuan, primarily due to a higher proportion of urea sales, which have a higher cost[41]. - The company is focusing on adjusting its product structure and expanding its customer base in response to market challenges[39]. - The company emphasizes continuous R&D and innovation to improve efficiency and reduce costs in its pharmaceutical intermediate business[34]. - The company has established long-term partnerships with key raw material suppliers to mitigate supply chain fluctuations[34]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The total number of shares is 366,122,195, with 46,200,690 shares (12.62%) under limited sale conditions and 319,921,505 shares (87.38%) under unlimited sale conditions[110]. - The largest shareholder, Ningbo Yinyi Holdings Co., Ltd., holds 23.76% of the shares, totaling 87,000,000 shares, which are currently pledged and frozen[112]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, by adhering to legal regulations and enhancing shareholder participation through online voting[77]. Environmental and Safety Measures - The company has implemented pollution control measures, with a wastewater treatment capacity of 500 tons per day, ensuring compliance with environmental standards[72]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[75]. - Safety production measures have been enhanced, with regular maintenance and training to meet safety production goals[78]. - Environmental protection efforts include the operation of wastewater treatment facilities that meet discharge standards, with over 90% data transmission rate for monitoring equipment[78]. Risks and Challenges - The company faces risks from drug procurement policies, which may lead to price declines in its products, and is taking measures to enhance product quality and reduce costs[62]. - The company is exposed to foreign exchange risks due to its export business, and plans to strengthen R&D and utilize financial tools to mitigate these risks[62]. - The controlling shareholder has been facing liquidity crises since 2019, with ongoing debt restructuring efforts[90]. Financial Reporting and Compliance - The semi-annual financial report has not been audited[86]. - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[162]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status[163].

广西河池化工股份有限公司 2022 年第一季度报告全文 证券代码：000953 证券简称：河化股份 公告编号：2022-021 广西河池化工股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 40,969,366.74 | 46,757,837.67 | -12.38% | | 归属于上市公司股东的净利润（元） | -1,431,517.79 | 5,459,9 ...

Financial Performance - The company's operating revenue for 2021 was ¥162,273,039.66, a decrease of 33.36% compared to ¥243,512,663.64 in 2020[20] - The net profit attributable to shareholders for 2021 was ¥10,018,330.39, down 67.62% from ¥30,939,202.60 in the previous year[20] - Basic earnings per share for 2021 were ¥0.03, a decline of 66.67% from ¥0.09 in 2020[21] - The net cash flow from operating activities decreased by 90.00%, amounting to ¥6,710,748.57 compared to ¥67,130,814.12 in 2020[21] - The company reported a total of ¥7.72 million in non-recurring gains and losses for 2021, a significant recovery from a loss of approximately ¥7.54 million in 2020[27] - The company achieved a total operating revenue of ¥162,273,039.66 in 2021, a decrease of 33.36% compared to the previous year[43] - The net profit attributable to shareholders was ¥10,018,330.39, down 67.62% year-on-year[43] - The pharmaceutical intermediates segment generated ¥89,702,497.45, accounting for 55.28% of total revenue, reflecting a 41.67% decline from 2020[45] - The fertilizer business contributed ¥68,291,410.11, representing 42.08% of total revenue, with a decrease of 22.49% year-on-year[45] Business Transformation and Strategy - The company has undergone a significant business transformation since 2020, shifting its focus to the research, production, and sales of chemical raw materials and pharmaceuticals[18] - The company emphasizes the importance of market conditions in achieving its operational goals and future plans[4] - The company is focused on the R&D and production of pharmaceutical intermediates, with a strong emphasis on new product development and process improvement[35] - The company utilizes a centralized procurement model to improve cost efficiency and reduce supply chain volatility[37] - The production strategy includes both general production based on sales forecasts and customized production according to client specifications[37] Market and Demand - The demand for chloroquine side chains surged in 2020 due to the COVID-19 pandemic, leading to increased product demand and prices, although the market normalized in 2021[32] - The company faced challenges due to high raw material prices and unstable energy supply, impacting production cycles and costs[42] - The domestic revenue was ¥112,500,990.05, down 31.98% year-on-year, while overseas revenue decreased by 36.28% to ¥49,772,049.61[45] Research and Development - The company’s R&D expenses in 2021 were ¥7,703,278.92, a decrease of 9.24% compared to ¥8,487,368.41 in 2020, while the R&D expenses accounted for 4.75% of operating revenue[56] - The company completed the optimization of several new processes, including methyl silane and valproic acid, aiming for industrial production and new economic growth points[56][57] - The number of R&D personnel decreased by 7.14% from 56 in 2020 to 52 in 2021, while the proportion of R&D personnel increased from 27.18% to 32.53%[57] Governance and Compliance - The company has established a robust internal management system to ensure compliance with laws and regulations, enhancing governance standards[82] - The company prioritizes transparent information disclosure, ensuring all shareholders have equal access to relevant information[85] - The company actively manages investor relations through various communication channels, fostering a positive relationship with investors[85] - The company has maintained effective internal control over financial reporting without any significant deficiencies or important deficiencies[129] - The internal control audit report issued on April 30, 2022, confirmed that the company maintained effective internal controls in all material respects as of December 31, 2021[134] Shareholder Relations - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[83] - The annual shareholders' meeting had a participation rate of 30.29% on May 18, 2021[88] - The first extraordinary shareholders' meeting had a participation rate of 43.76% on September 14, 2021[89] - The company has not reported any penalties from securities regulatory agencies for its current and recently departed directors, supervisors, and senior management[108] Environmental and Social Responsibility - The company has invested in environmental protection facilities and improved production processes to achieve energy conservation and emission reduction goals[147] - The company has not faced any administrative penalties related to environmental issues during the reporting period[145] - The company has not initiated any poverty alleviation or rural revitalization projects during the reporting period[148] Future Outlook - The company plans to enhance cooperation with downstream pharmaceutical clients and increase investment in technology development and business expansion[74] - New product development will focus on T51, T22, and T62 intermediates, with efforts to accelerate their market introduction[75] - The company anticipates risks from drug procurement policies that may lead to price declines for intermediate products, prompting a need for cost control and quality improvement[77] - The company has provided a revenue guidance of CNY 1.8 billion for the fiscal year 2022, which reflects an expected growth of 20%[95] Related Party Transactions and Commitments - The company has committed to avoid any form of fund occupation or illegal appropriation of assets from the listed company[153] - The company has pledged to ensure that no direct or indirect means will be used to seek control over the board of directors of the listed company[153] - The commitments made by the actual controller will remain valid unless they cease to be the controlling shareholder[150] - The company has undertaken to minimize related transactions and ensure they are conducted at market prices[150] Employee and Management Information - The total number of employees at the end of the reporting period is 182, with 16 in the parent company and 166 in major subsidiaries[122] - The company has a complete business operation system and does not engage in substantial competition with its controlling shareholders[87] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 2.0772 million CNY[111]

广西河池化工股份有限公司 2021 年第三季度报告 证券代码：000953 证券简称：河化股份 公告编号：2021-039 广西河池化工股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 增减 | | 比上年同期增减 | | 营业收入（元） | 40,097,269.40 | 24.06% | 133,381,231.81 | -40.01% ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[20]. - The net profit attributable to shareholders was ¥2,856,763.21, down 93.73% from ¥45,572,911.22 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥1,751,745.52, a decline of 96.15% compared to ¥45,441,914.64 in the previous year[20]. - The net cash flow from operating activities was ¥7,375,714.21, representing an 83.71% decrease from ¥45,285,557.86 in the same period last year[20]. - Basic earnings per share were ¥0.0078, down 93.95% from ¥0.1290 in the previous year[20]. - The company's revenue for the reporting period was ¥93.28 million, a decrease of 50.91% compared to ¥190.02 million in the same period last year[36]. - The net profit for the reporting period was ¥334.96 million, down 93.18% from the previous year[36]. - The gross profit margin for the pharmaceutical intermediates segment was 44.64%, down 17.19% year-on-year, while the gross profit margin for the fertilizer business was 1.43%, down 0.20% year-on-year[40]. - The net cash flow from operating activities decreased by 83.71% to ¥7,375,714.21, primarily due to a reduction in sales revenue[40]. - The company's total operating revenue for the reporting period was ¥93,283,962.41, a decrease of 50.91% compared to ¥190,023,890.74 in the same period last year[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥382,243,744.99, an increase of 1.58% from ¥376,292,912.19 at the end of the previous year[20]. - The net assets attributable to shareholders at the end of the reporting period were ¥169,847,014.84, up 1.71% from ¥166,990,251.63 at the end of the previous year[20]. - The company's total assets included cash and cash equivalents of ¥80,607,138.98, representing 21.09% of total assets, primarily due to the redemption of bank wealth management products[45]. - The company's total liabilities increased to CNY 196,468,125.83 from CNY 193,866,917.27, reflecting a growth of about 0.8%[122]. - The company's non-current assets decreased to CNY 245,166,701.57 from CNY 248,794,081.79, showing a decline of approximately 1.1%[121]. - The company's total liabilities at the end of the period were CNY 701,900,568.72, indicating a high leverage ratio[144]. Research and Development - The company continues to conduct small-scale research and pilot projects, including ongoing optimization of the T53 (Nebivolol Epoxide) process to reduce raw material costs[36]. - The company has developed new processes for T55 (Valproic Acid) and T57 (N-desmethylclobazam), with T57 samples already sent to customers for validation[36]. - The company emphasizes R&D and has a dedicated project management system to improve efficiency and reduce costs[30]. - Research and development expenses amounted to ¥3,850,668.12, a decrease of 18.18% from ¥4,706,454.31 in the previous year[40]. - The company's research and development expenses for the first half of 2021 were CNY 3,850,668.12, a decrease of 18.19% from CNY 4,706,454.31 in the first half of 2020[128]. Market and Sales - Domestic sales accounted for 73.53% of total revenue, amounting to ¥68,588,445.33, while overseas sales accounted for 26.47%, totaling ¥24,695,517.08, reflecting decreases of 47.04% and 59.20% respectively[39]. - The company has a high market share and quality-leading products, with self-operated import and export rights[32]. - The company has a flexible production model that allows for customization based on client needs, particularly for Vitamin D3 intermediates[31]. - The company has maintained a stable relationship with major clients, which is crucial for its revenue stability[58]. Environmental and Regulatory Compliance - The company emphasizes environmental protection and has taken measures to control pollution during production processes[55]. - The company has completed the construction of pollution control facilities, including a waste gas collection and treatment system with a design capacity of 30,000 m³/h and a wastewater treatment plant with a design capacity of 500 t/d[69]. - The total discharge of chemical oxygen demand (COD) is 1.55 t/a, which is below the approved discharge limit of 2.57 t/a, indicating no exceedance[69]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[73]. - The company has submitted a self-monitoring plan for environmental protection, which includes monitoring of wastewater, waste gas, and noise pollution[72]. Corporate Governance - The company has not made any changes to its board of directors or senior management during the reporting period[64]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[81]. - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[77]. - The semi-annual financial report has not been audited[79]. Financial Management - The company has a receivable from related parties amounting to 10,683.57 million CNY, with an interest rate of 4.35%[87]. - The company has a payable to related parties totaling 2,282.93 million CNY, also at an interest rate of 4.35%[87]. - The company utilized related party borrowings primarily for short-term cash flow management, ensuring operational stability without impacting financial results[87]. - The company has invested 7,650 million CNY in bank wealth management products, with an outstanding balance of 704.6 million CNY[95]. - The company reported a total share count of 366,122,195, with 25,862,068 shares released from lock-up on March 26, 2021[101]. Future Outlook - The company plans to strengthen its market expansion and product development strategies to mitigate risks associated with high customer concentration[58]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[144].

证券代码：000953 证券简称： *ST 河化 公告编号：2021-017 广西河池化工股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，广西河池化工股份有限公司 （以下简称"公司"）将参加由广西上市公司协会、深圳市全景网络 有限公司共同举办的"2021 年广西地区上市公司投资者网上集体接 待日活动"，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可以登陆"全景•投资者关系互动平台"网站 （http：//ir.p5w.net）参与公司本次投资者集体接待日活动，活动 时间为 2021 年 5 月 21 日（星期五）15:30 至 17:00。 届时公司董事长总经理覃宝明先生、财务总监卢勇帐先生、董事 会秘书覃丽芳女士（如有特殊情况，参会人员可能进行调整）将通过 网络在线问答互动的形式，与投资者就公司治理、发展经营情况、融 资情况和可持续发展等投资者关注的问题进行交流。期间，公司高管 将全程在线，通过全景网投资者关系互动平台 ...

Financial Performance - Revenue for Q1 2021 was CNY 46,757,837.67, a decrease of 21.97% compared to CNY 59,919,555.56 in the same period last year[7] - Net profit attributable to shareholders was CNY 5,459,994.36, down 37.05% from CNY 8,672,939.51 year-on-year[7] - Net profit excluding non-recurring gains and losses was CNY 4,511,985.86, a decline of 47.11% compared to CNY 8,530,236.73 in the previous year[7] - Total operating revenue for Q1 2021 was CNY 46,757,837.67, a decrease of 21.9% compared to CNY 59,919,555.56 in the same period last year[34] - Net profit for Q1 2021 was CNY 5,987,334.49, a decline of 36.1% from CNY 9,460,412.29 in Q1 2020[35] - The company's gross profit margin for Q1 2021 was approximately 12.5%, compared to 20.1% in Q1 2020[34] - The total profit for the first quarter was -2,085,639.26 CNY, an improvement from -2,589,628.39 CNY in the previous year, indicating a reduction in losses by approximately 19.5%[39] Cash Flow - Operating cash flow net amount was CNY 2,363,926.60, a significant drop of 86.88% from CNY 18,019,109.23 in the same period last year[7] - Net cash flow from operating activities decreased by 15.6552 million yuan, a decline of 86.88%, mainly due to reduced sales collections in the current period[16] - Cash inflow from sales of goods and services was 44,958,056.42 CNY, compared to 97,273,784.54 CNY in the previous year, representing a decline of approximately 53.8%[41] - The net cash flow from investing activities was 27,810,560.23 CNY, a significant turnaround from -19,966,081.44 CNY in the previous year, indicating a positive change in investment cash flow[42] - The company’s cash flow from financing activities was -419,812.49 CNY, compared to a positive inflow of 112,586,801.07 CNY in the same period last year, indicating a shift in financing strategy[42] - The cash outflow for purchasing goods and services was 35,564,721.21 CNY, compared to 69,746,330.52 CNY in the previous year, a reduction of about 49.1%[42] Assets and Liabilities - Total assets increased by 5.45% to CNY 396,787,379.14 from CNY 376,292,912.19 at the end of the previous year[7] - Total current assets as of March 31, 2021, amounted to 149.968 million yuan, an increase from 127.499 million yuan as of December 31, 2020[26] - Total assets as of March 31, 2021, were 396.787 million yuan, compared to 376.293 million yuan as of December 31, 2020[28] - Total liabilities as of March 31, 2021, were 208.374 million yuan, an increase from 193.867 million yuan as of December 31, 2020[28] - The total liabilities as of the end of Q1 2021 were CNY 167,029,534.43, an increase from CNY 165,139,066.89 at the end of the previous quarter[32] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,518[11] - The company’s total equity as of the end of Q1 2021 was CNY 116,465,100.02, down from CNY 118,550,739.28 in the previous quarter[32] - The company reported a net loss of 711.074 million yuan in retained earnings as of March 31, 2021, compared to a loss of 716.534 million yuan as of December 31, 2020[28] Expenses - Operating costs decreased by 7.9194 million yuan, a decline of 19.87%, mainly due to increased sales of pharmaceutical intermediates last year caused by the pandemic[16] - Management expenses increased by 1.5624 million yuan, up 38.79%, primarily due to maintenance of the production system during the current period[16] - Research and development expenses for Q1 2021 amounted to CNY 1,749,251.19, slightly down from CNY 1,806,866.65 in the previous year[35] - The company reported a decrease in management expenses to CNY 5,590,043.98 from CNY 4,027,612.01 in the previous year[35] Inventory and Receivables - Accounts receivable increased by CNY 15,787,500, up 207.23%, due to increased product sales with outstanding payments[15] - Inventory decreased by CNY 9,006,400, down 33.86%, attributed to increased sales volume leading to reduced stock[15] - Contract liabilities increased by CNY 13,094,200, up 338.36%, due to increased prepayments from customers for fertilizer purchases[15] Other Information - The company did not report any new product developments or market expansions during this quarter[45]

Financial Performance - The company's operating revenue for 2020 was CNY 243,512,663.64, representing a 75.62% increase compared to CNY 138,660,130.33 in 2019[19] - The net profit attributable to shareholders for 2020 was CNY 30,939,202.60, a significant turnaround from a loss of CNY 60,916,555.09 in 2019, marking a 150.79% improvement[19] - The net cash flow from operating activities reached CNY 67,130,814.12, a remarkable increase of 703.99% from a negative cash flow of CNY 11,114,589.37 in the previous year[19] - The basic earnings per share for 2020 was CNY 0.090, compared to a loss of CNY 0.210 per share in 2019, reflecting a 142.86% increase[20] - The total assets at the end of 2020 amounted to CNY 376,292,912.19, which is a 9.17% increase from CNY 344,683,621.33 at the end of 2019[20] - The net assets attributable to shareholders surged to CNY 166,990,251.63, a 612.73% increase from CNY 23,429,825.28 in 2019[20] - The weighted average return on net assets for 2020 was 25.12%, a notable improvement from 0.00% in 2019[20] - The company reported a significant reduction in financial expenses by 64.63% to CNY 8.70 million due to the repayment of CNY 420 million in loans following the asset restructuring in 2019[56] Business Transformation - The company underwent a significant asset restructuring in 2020, changing its main business to the research, production, and sales of chemical raw materials and pharmaceuticals[17] - The company achieved a transformation from traditional fertilizer manufacturing to the research, production, and sales of pharmaceutical intermediates through a major asset restructuring in 2020[80] - The company underwent a major asset restructuring in December 2019, selling less profitable urea production assets and acquiring Nansong Pharmaceutical to enter the pharmaceutical intermediate sector[28] - The company is actively pursuing new product development and market expansion in the pharmaceutical sector, focusing on various intermediate products[57] Revenue Breakdown - The pharmaceutical intermediates segment generated CNY 153.77 million, accounting for 63.15% of total revenue, with a gross margin of 57.99%[45] - The fertilizer business revenue decreased by 35% to CNY 88.10 million, with a gross margin of only 1.66%[45] - The revenue from pharmaceutical intermediates was CNY 153.77 million in 2020, a 57.45% increase from CNY 97.66 million in 2019, with a gross margin of 57.99%[52] Cash Flow and Investments - The net cash flow from operating activities increased by 703.99% to ¥67,130,814.12 compared to a loss of ¥11,114,589.37 in the previous year[59] - Total cash inflow from operating activities rose by 73.82% to ¥268,943,770.14, driven by increased demand for products due to the COVID-19 pandemic[60] - Total cash outflow from operating activities increased by 21.69% to ¥201,812,956.02, primarily due to higher procurement of raw materials[60] - Cash inflow from investment activities surged significantly, with a reported increase of 25,824,075,150.00% to ¥258,240,752.50, attributed to the inclusion of Nansong Pharmaceutical in the consolidation scope[60] Shareholder and Dividend Information - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company reported a net profit attributable to ordinary shareholders of 30,939,202.60 in 2020, with a cash dividend payout ratio of 0.00%[86] - No cash dividends were distributed in the reporting period, and the company plans not to issue cash dividends or bonus shares in the upcoming year[87] - The company has not proposed any profit distribution or capital reserve transfer plans in recent years due to negative retained earnings[85] Market Presence and Strategy - The company expanded its market presence, with domestic sales accounting for 67.92% of total revenue and international sales contributing 32.08%[45] - The sales strategy includes leveraging a strong reputation and established sales channels for urea products, allowing for flexible adjustments based on market demand[33] - The company is considering strategic acquisitions to enhance its product portfolio and market presence[175] Research and Development - The company emphasizes new product R&D and has established a dedicated project management system to enhance efficiency and reduce costs[29] - The company has been actively investing in R&D, completing several projects including the production pilot tests for various pharmaceutical intermediates[40] - Research and development expenses amounted to CNY 8.49 million, representing 3.49% of total revenue, marking a 100% increase due to the inclusion of Nansong Pharmaceutical[58] Corporate Governance and Compliance - The company has fulfilled its commitments regarding competition and related transactions as of the reporting period end[88] - The actual controller and shareholders have committed to avoiding and minimizing related party transactions with the company and its subsidiaries[90] - The company is committed to maintaining transparency and fairness in all transactions to protect the legal rights of shareholders[90] Environmental and Social Responsibility - The company has invested in environmental protection facilities and improved production processes to achieve energy conservation and emission reduction[125] - The company has actively participated in social welfare activities, donating over 200,000 CNY for pandemic prevention efforts[125] - The company’s wastewater and waste gas emissions have met industry standards, with no exceedances reported[127][128] Employee and Management Information - The total number of employees in the company is 188, with 128 in production, 5 in sales, 26 in technical roles, 8 in finance, and 19 in administration[189] - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 184.69 million yuan[188] - The company has established a comprehensive training system for employees, enhancing their professional skills and overall quality[192] Legal and Regulatory Matters - The company is involved in a legal dispute with Alkaloida Chemical Company Zrt regarding overdue payments totaling 673,500.00 USD[106] - The company has no significant penalties or rectification situations during the reporting period[107] - The company reported no major related party transactions during the reporting period[110]